<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003383" GROUP_ID="DEPRESSN" ID="389101020812404434" MERGED_FROM="" MODIFIED="2010-05-11 13:50:20 +0200" MODIFIED_BY="Jane Dennis" REVIEW_NO="003" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.2">
<COVER_SHEET MODIFIED="2010-05-11 13:50:20 +0200" MODIFIED_BY="Jane Dennis">
<TITLE>Kava extract versus placebo for treating anxiety</TITLE>
<CONTACT MODIFIED="2010-05-11 13:50:20 +0200" MODIFIED_BY="Jane Dennis"><PERSON ID="13918" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Max</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Pittler</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>pittler@cochrane.de</EMAIL_1><EMAIL_2>max.pittler@pms.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>German Cochrane Center</DEPARTMENT><ORGANISATION>Department of Medical Biometry and Statistics</ORGANISATION><ADDRESS_1>University Medical Center Freiburg</ADDRESS_1><ADDRESS_2>Berliner Allee 29</ADDRESS_2><CITY>Freiburg</CITY><ZIP>79110</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 203 6695</PHONE_1><FAX_1>+49 761 203 6712</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-05-11 13:50:20 +0200" MODIFIED_BY="Jane Dennis"><PERSON ID="13918" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Max</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Pittler</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>pittler@cochrane.de</EMAIL_1><EMAIL_2>max.pittler@pms.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>German Cochrane Center</DEPARTMENT><ORGANISATION>Department of Medical Biometry and Statistics</ORGANISATION><ADDRESS_1>University Medical Center Freiburg</ADDRESS_1><ADDRESS_2>Berliner Allee 29</ADDRESS_2><CITY>Freiburg</CITY><ZIP>79110</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 203 6695</PHONE_1><FAX_1>+49 761 203 6712</FAX_1></ADDRESS></PERSON><PERSON ID="7423" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Edzard</FIRST_NAME><LAST_NAME>Ernst</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Director</POSITION><EMAIL_1>edzard.ernst@pms.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Complementary Medicine</DEPARTMENT><ORGANISATION>Peninsula Medical School, Universities of Exeter and Plymouth</ORGANISATION><ADDRESS_1>25 Victoria Park Road</ADDRESS_1><CITY>Exeter</CITY><ZIP>EX2 4NT</ZIP><REGION>Devon</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0) 1392 430802</PHONE_1><FAX_1>+44 (0) 1392 427562</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-03-12 09:32:47 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="1" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="1" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="10" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-27 06:52:06 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-27 06:52:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Contact authors' details amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-04-12 12:54:00 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-12 12:54:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details of contact/first author updated; search dates synchronised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-12 09:21:39 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2010-03-12 09:23:19 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="11" YEAR="2002"/>
<DESCRIPTION>
<P>Feedback was added, together with a response, on 20 November 2002.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="18" MONTH="11" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-03-12 09:26:32 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-03-12 09:26:32 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-03-12 09:26:32 +0000" MODIFIED_BY="[Empty name]">
<NAME>Peninsula Medical School, Universities of Exeter and Plymouth</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-04-27 06:54:37 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-02 13:31:26 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-02 13:31:26 +0000" MODIFIED_BY="[Empty name]">Kava extract for treating anxiety</TITLE>
<SUMMARY_BODY>
<P>Systematic literature searches were conducted to assess the evidence for or against the effectiveness of kava extract for treating anxiety. Twenty-two potentially relevant double-blind, placebo-controlled RCTs were identified. Twelve trials met the inclusion criteria. The meta-analysis of seven trials suggests a significant treatment effect for the total score on the Hamilton Anxiety Scale in favour of kava extract. Few adverse events were reported in the reviewed trials, which were all mild, transient and infrequent. These data imply that, compared with placebo, kava extract might be an effective symptomatic treatment for anxiety although, at present, the size of the effect seems to be small. Rigorous trials with large sample sizes are needed to clarify the existing uncertainties. Particularly long-term safety studies of kava are needed. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-04-27 06:52:34 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Constraints on resources and time often render treatments for anxiety such as psychological interventions impracticable. While synthetic anxiolytic drugs are effective, they are often burdened with adverse events. Other options which are effective and safe are of considerable interest and a welcome addition to the therapeutic repertoire. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness and safety as reported in rigorous clinical trials of kava extract compared with placebo for treating anxiety. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-04-27 06:52:34 +0100" MODIFIED_BY="[Empty name]">
<P>All publications describing (or which might describe) randomised, double-blind, placebo-controlled trials of kava extract for anxiety were sought through electronic searches on EMBASE (1974 to January 2005), MEDLINE (1951 to January 2005), AMED (1985 to January 2005)), CISCOM (inception until August 2002) and Central/CCTR and CCDANCTR (issue 1, 2005). The search terms that were used were kava, kawa, kavain, Piper methysticum and Rauschpfeffer (German common name for Piper methysticum). Additionally, manufacturers of kava preparations and experts on the subject were contacted and asked to contribute published and unpublished material. Hand-searches of a sample of relevant medical journals (Erfahrungsheilkunde 1996 - 2005, Forsch Komplementärmed Klass Naturheilkd 1994 - 2005, Phytomed 1994 - 2005, Alt Comp Ther 1995 - 2005), conference proceedings (e.g. FACT - Focus on Alternative and Complementary Therapies 1996 - 2005) and our own collection of papers were conducted. No restrictions regarding the language of publication were imposed.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>To be included studies were required to be randomised, controlled trials (RCTs), i.e. trials with a randomised generation of allocation sequences, and conducted placebo-controlled and double-blind, i.e. trials with blinding of patients and care providers. Trials using oral preparations containing kava extract as the only component (mono-preparation) were considered. Trials using single constituents of kava extract alone, assessing kava extract as one of several active components in a combination preparation or as a part of a combination therapy were excluded. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted systematically according to patient characteristics, interventions and results. Methodological quality of all trials was evaluated using the standard scoring system developed by Jadad and colleagues. The screening of studies, selection, data extraction, validation and the assessment of methodological quality were performed independently by the two reviewers. Disagreements in the evaluation of individual trials were largely due to reading errors and were resolved through discussion. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twelve double-blind RCTs (n=700) met the inclusion criteria. The meta-analysis was done on seven studies using the total score on the Hamilton Anxiety (HAM-A) scale as a common outcome measure. The result suggests a significant effect towards a reduction of the HAM-A total score in patients receiving kava extract compared with patients receiving placebo (weighted mean difference: 3.9, 95% confidence interval: 0.1 to 7.7; p = 0.05; n = 380). The results of the five studies that were not submitted to meta-analysis largely support these findings. Adverse events as reported in the reviewed trials were mild, transient and infrequent. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Compared with placebo, kava extract is an effective symptomatic treatment for anxiety although, at present, the size of the effect seems small. The effect lacks robustness and is based on a relatively small sample. The data available from the reviewed studies suggest that kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required. Rigorous trials with large sample sizes are needed to clarify the existing uncertainties. Also, long-term safety studies of kava are required.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-04-27 06:54:37 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-04-27 06:54:37 +0100" MODIFIED_BY="[Empty name]">
<P>Anxiety disorders commonly occur, seriously impair mental health (<LINK REF="REF-Myers-1984" TYPE="REFERENCE">Myers 1984</LINK>), and are of considerable importance in terms of economic burden to society. Data from the United States National Comorbidity Survey suggests a one-year prevalence of 17% and a lifetime prevalence of almost 25% (<LINK REF="REF-Kessler-1994" TYPE="REFERENCE">Kessler 1994</LINK>), while annual costs of anxiety disorders have been estimated at approximately $42.3 billion in 1990, which is equivalent to about $1542 per patient (<LINK REF="REF-Greenberg-1999" TYPE="REFERENCE">Greenberg 1999</LINK>). In the majority of cases, patients are treated by general practitioners (<LINK REF="REF-Walley-1994" TYPE="REFERENCE">Walley 1994</LINK>, <LINK REF="REF-Robinson-1993" TYPE="REFERENCE">Robinson 1993</LINK>; <LINK REF="REF-Deans-1992" TYPE="REFERENCE">Deans 1992</LINK>) and benzodiazepines are commonly used. However, these are associated with adverse events, which include dependence, sedation and memory impairment (<LINK REF="REF-Priest-1988" TYPE="REFERENCE">Priest 1988</LINK>; <LINK REF="REF-Gorman-1990" TYPE="REFERENCE">Gorman 1990</LINK>; <LINK REF="REF-Hunt-1991" TYPE="REFERENCE">Hunt 1991</LINK>). Constraints on resources and time often render other treatments such as psychological interventions impracticable. Data from a nationally representative survey conducted in the United States suggest that anxiety patients frequently use complementary and alternative therapies (<LINK REF="REF-Kessler-2001" TYPE="REFERENCE">Kessler 2001</LINK>; <LINK REF="REF-Astin-1998" TYPE="REFERENCE">Astin 1998</LINK>) and one possible option is kava extract (<LINK REF="REF-Brevoort-1998" TYPE="REFERENCE">Brevoort 1998</LINK>).</P>
<P>Kava is the beverage prepared from the rhizome of the kava plant (Piper methysticum Forst.) (<LINK REF="REF-Cawte-1985" TYPE="REFERENCE">Cawte 1985</LINK>). Throughout the South Pacific extracts of kava have been used for recreational and medicinal purposes. Traditionally, it was used to treat a variety of ailments such as gonorrhoea and to induce relaxation and sleep but also to counteract fatigue (<LINK REF="REF-Lebot-1992" TYPE="REFERENCE">Lebot 1992</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>). The rhizome of cultivated P. methysticum is used as raw material for the production of kava extract (<LINK REF="REF-Habs-1994" TYPE="REFERENCE">Habs 1994</LINK>). In 1998, it was among the top selling herbs in the US totalling approximately $8 million in annual retail sales (<LINK REF="REF-Brevoort-1998" TYPE="REFERENCE">Brevoort 1998</LINK>). In 2000, this had increased to approximately $15 million (<LINK REF="REF-Blumenthal-2001" TYPE="REFERENCE">Blumenthal 2001</LINK>). Uncontrolled clinical studies have suggested that kava may be beneficial for treating anxiety (e.g. <LINK REF="REF-Melville-1964" TYPE="REFERENCE">Melville 1964</LINK>; <LINK REF="REF-Lemert-1967" TYPE="REFERENCE">Lemert 1967</LINK>). Data from a previous review confirmed these early findings and suggested a significant reduction of the Hamilton-Anxiety (HAM-A) total score of 9.7 points in favor of kava compared with placebo (<LINK REF="REF-Pittler-2000a" TYPE="REFERENCE">Pittler 2000a</LINK>). The exact mechanism of action of kava is unclear. New data from randomised, controlled trials (RCTs) have become available, which prompted us to update this Cochrane review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effectiveness and safety as reported in rigorous clinical trials of kava extract compared with placebo for treating anxiety. </P>
</OBJECTIVES>
<METHODS MODIFIED="2010-03-12 09:29:03 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>To be included studies were required to be RCTs, i.e. trials with a randomised generation of allocation sequences, and conducted placebo-controlled and double-blind, i.e. trials with blinding of patients and care providers . </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Trial participants had to be patients, who were suffering from anxiety.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials using oral preparations containing kava extract as the only component (mono-preparation) were considered. Trials using single constituents of kava extract alone, assessing kava extract as one of several active components in a combination preparation or as a part of a combination therapy were excluded. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Trials assessing clinical outcome measures related to anxiety (e.g.Hamilton Anxiety scale) were included. Of primary interest is the change of baseline to post treatment data. Data on the safety of kava are described as they were reported in the reviewed trials. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative Review Group search strategy. <BR/>All publications describing (or which might describe) randomised, double-blind, placebo-controlled trials of kava extract for anxiety were sought through electronic searches. Databases were searched from their inception: EMBASE (1974 to January 2005), MEDLINE (1951 to January 2005), AMED (1985 to January 2005)), CISCOM (Research Council for Complementary Medicine, London; until August 2002) and Central/CCTR and CCDANCTR (Cochrane Collaborative Depression, Anxiety &amp; Neurosis Controlled Trials register) on the Cochrane Library (issue 1, 2005). </P>
<P>The search terms that were used were kava, kawa, kavain, Piper methysticum and Rauschpfeffer (German common name for Piper methysticum). Manufacturers of kava preparations and experts on the subject were contacted and asked to contribute published and unpublished material. </P>
<P>Hand-searches of a sample of relevant medical journals (Erfahrungsheilkunde 1996 - 2005, Forsch Komplementärmed Klass Naturheilkd 1994 - 2005, Phytomed 1994 - 2005, Alt Comp Ther 1995 - 2005), conference proceedings (e.g. FACT - Focus on Alternative and Complementary Therapies 1996 - 2005) and our own collection of papers were conducted. </P>
<P>The bibliographies of all papers located were searched for further trials. No restrictions regarding the language of publication were imposed.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-03-12 09:29:03 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Study selection</HEADING>
<P>The screening of studies, selection, data extraction, validation and the assessment of methodological quality were performed independently by the two reviewers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Articles in languages other than English or German were translated in-house. Data were extracted systematically according to the methods used, outcome measures, patient characteristics, interventions, results and adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality</HEADING>
<P>Methodological quality was evaluated using the scoring system developed by Jadad and colleagues (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), which quantifies the likelihood of bias inherent in the trials, based on the description of randomisation, blinding and withdrawals. Disagreements in the evaluation of trials were largely due to reading errors and were resolved through discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>Meta-analysis was performed using standard meta-analysis software (RevMan 4.2.7, Update Software Ltd., Oxford, England). It uses the inverse of the variance to assign a weight to the mean of the within-study treatment effect. For most studies, however, the information was insufficient to allow us to directly calculate the variance of the pre-intervention to post-intervention change. The Cochrane Collaboration suggests to impute the variance of the change by assuming a correlation factor of 0.4 between pre-intervention and post-intervention values. The variance of the change was imputed using this correlation factor and then used to assign a weight to the mean of the within-study treatment effect. In addition, further information was sought through contacting the authors of the original trials and the manufacturer of the preparations that were used. The meta-analysis was performed using the weighted mean difference. </P>
<P>The treatment effect was calculated using a random effects model. The chi-square test for heterogeneity tested whether the distribution of the results was compatible with the assumption that inter-trial differences were attributable to chance variation alone. </P>
<P>Sensitivity analyses were performed post-hoc to test the robustness of the main analysis. For the meta-analyses the data were re-calculated based on the original raw data except for Conn 2001.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For this update, one new study was identified (<LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>). Previously unpublished trials are now published (<LINK REF="STD-Gastpar-2003" TYPE="STUDY">Gastpar 2003</LINK>; <LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>). In total, twenty-two potentially relevant double-blind, placebo-controlled RCTs were identified (<LINK REF="STD-Lehmann-1998" TYPE="STUDY">Lehmann 1998</LINK>; <LINK REF="STD-Lehmann-1996" TYPE="STUDY">Lehmann 1996</LINK>; <LINK REF="STD-Lehmann-1989" TYPE="STUDY">Lehmann 1989</LINK>; <LINK REF="STD-Lindenberg-1990" TYPE="STUDY">Lindenberg 1990</LINK>; <LINK REF="STD-Bhate-1992" TYPE="STUDY">Bhate 1992</LINK>; <LINK REF="STD-Bhate-1989" TYPE="STUDY">Bhate 1989</LINK>; <LINK REF="STD-M_x00f6_ller-1992" TYPE="STUDY">Möller 1992</LINK>; <LINK REF="STD-M_x00f6_ller-1989" TYPE="STUDY">Möller 1989</LINK>; <LINK REF="STD-Staedt-1991" TYPE="STUDY">Staedt 1991</LINK>; <LINK REF="STD-Malsch-2001" TYPE="STUDY">Malsch 2001</LINK>; <LINK REF="STD-Kinzler-1991" TYPE="STUDY">Kinzler 1991</LINK>; <LINK REF="STD-Warnecke-1991" TYPE="STUDY">Warnecke 1991</LINK>; <LINK REF="STD-Warnecke-1990" TYPE="STUDY">Warnecke 1990</LINK>; <LINK REF="STD-Warnecke-1986" TYPE="STUDY">Warnecke 1986</LINK>; <LINK REF="STD-Warnecke-1989" TYPE="STUDY">Warnecke 1989</LINK>; <LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>; <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="STD-De-Leo-2001" TYPE="STUDY">De Leo 2001</LINK>; <LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>; <LINK REF="STD-Gastpar-2003" TYPE="STUDY">Gastpar 2003</LINK>; <LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>). Two studies were duplicate publications (<LINK REF="STD-Lehmann-1996" TYPE="STUDY">Lehmann 1996</LINK>; <LINK REF="STD-Bhate-1992" TYPE="STUDY">Bhate 1992</LINK>), eight others were excluded because they were either not performed with a kava extract monopreparation (<LINK REF="STD-Warnecke-1989" TYPE="STUDY">Warnecke 1989</LINK>; <LINK REF="STD-Warnecke-1986" TYPE="STUDY">Warnecke 1986</LINK>), were performed as part of a combination therapy (<LINK REF="STD-De-Leo-2001" TYPE="STUDY">De Leo 2001</LINK>) or were performed using kavain (<LINK REF="STD-M_x00f6_ller-1992" TYPE="STUDY">Möller 1992</LINK>; <LINK REF="STD-M_x00f6_ller-1989" TYPE="STUDY">Möller 1989</LINK>; <LINK REF="STD-Lehmann-1989" TYPE="STUDY">Lehmann 1989</LINK>; <LINK REF="STD-Staedt-1991" TYPE="STUDY">Staedt 1991</LINK>; <LINK REF="STD-Lindenberg-1990" TYPE="STUDY">Lindenberg 1990</LINK>). Twelve double-blind, placebo-controlled RCTs met all inclusion criteria and were reviewed. Seven trials assessed a common outcome measure and provided data, which were suitable for meta-analysis (<LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>; <LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>; <LINK REF="STD-Malsch-2001" TYPE="STUDY">Malsch 2001</LINK>; <LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>; <LINK REF="STD-Kinzler-1991" TYPE="STUDY">Kinzler 1991</LINK>; <LINK REF="STD-Warnecke-1991" TYPE="STUDY">Warnecke 1991</LINK>). All, except one (<LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>), used the same preparation (WS1490), which is standardised to 70 % kavalactone content and is produced by the same manufacturer. Key data from all included trials are presented in the characteristics of included trials table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Six trials scored the maximum of 5 points on the Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Four of seven trials that could be included in the meta-analysis scored the maximum of 5 points, while three other trials lacked either a description of randomization procedures (<LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>; <LINK REF="STD-Malsch-2001" TYPE="STUDY">Malsch 2001</LINK>) or lacked a description of randomization and double-blinding procedures (<LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>A total of twelve double-blind RCTs (n=700) were reviewed (Characteristics of included studies table). Six trials reported adverse events experienced by patients receiving kava extract. Stomach complaints, restlessness, drowsiness, tremor, headache and tiredness were reported most frequently. Four trials comprising 30% of patients in the reviewed trials report the absence of adverse events while taking kava extract. None of the trials reported any hepatotoxic events. Seven of the reviewed trials (<LINK REF="STD-Gastpar-2003" TYPE="STUDY">Gastpar 2003</LINK>; <LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>; Conn 2001 reported in <LINK REF="REF-Connor-2001" TYPE="REFERENCE">Connor 2001</LINK>; <LINK REF="STD-Malsch-2001" TYPE="STUDY">Malsch 2001</LINK>; <LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>; <LINK REF="STD-Warnecke-1991" TYPE="STUDY">Warnecke 1991</LINK>) measured liver enzyme levels as safety parameters and report no clinically signifcant changes.<BR/>
<BR/>Data from seven trials (n=380) assessed a common outcome measure - the total score on the HAM-A scale - and were included in the meta-analysis (<LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>; <LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>; <LINK REF="STD-Malsch-2001" TYPE="STUDY">Malsch 2001</LINK>; <LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>; <LINK REF="STD-Kinzler-1991" TYPE="STUDY">Kinzler 1991</LINK>; <LINK REF="STD-Warnecke-1991" TYPE="STUDY">Warnecke 1991</LINK>). 74 % of these patients (n = 282) were diagnosed according to the criteria of the American Psychiatric Association (DSM-III-R, DSM-IV). All trials used the HAM-A total score at baseline as an inclusion criterion and four trials included patients if the total score was 19 or above (Characteristics of included studies table). The result of the meta-analysis suggests an effect towards a reduction of the HAM-A total score in patients receiving kava extract compared with patients receiving placebo (weighted mean difference: 3.9, 95% confidence interval: 0.1 to 7.7; p = 0.05; n = 380). The chi-square test indicated heterogeneity (chi square = 27.5; p = 0.0001 ). Visual inspection of the forest plot identified two outlier (<LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>; <LINK REF="STD-Warnecke-1991" TYPE="STUDY">Warnecke 1991</LINK>), which were mainly responsible for the heterogeneity. <LINK REF="STD-Warnecke-1991" TYPE="STUDY">Warnecke 1991</LINK> was the only one that included only women with anxiety due to climacteric syndrome. <LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK> was the only trial that did not use the kava preparation WS1490. Other potential sources of clinical heterogeneity (dose of kava, duration of treatment, degree of baseline severity or setting) could not be identified (Characteristics of included studies table). Removing these trials and pooling the data of the remaining five trials (chi square = 9.0; p = 0.06) suggests a significant reduction of the HAM-A total score in patients receiving kava extract compared with patients receiving placebo (weighted mean difference: 3.4, 95% confidence interval: 0.5 to 6.4; p = 0.02; n = 305). </P>
<P>Other sensitivity analyses testing the robustness of the main analysis assessed whether including only the data of patients with non-psychotic anxiety diagnosed according to the criteria of the American Psychiatric Association (DSM-III-R, DSM-IV) criteria (<LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Lehrl-2004" TYPE="STUDY">Lehrl 2004</LINK>; <LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK>; <LINK REF="STD-Malsch-2001" TYPE="STUDY">Malsch 2001</LINK>; <LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>) would alter the direction of the result. The meta-analysis of these data (chi square = 5.8; p = 0.2) suggests a non-significant effect (weighted mean difference: 1.0, 95% confidence interval: -1.3 to 3.3; p = 0.4; n = 282). The analysis of trials assessing outpatients with non-psychotic anxiety patients and a HAM-A total score of 19 or above (<LINK REF="STD-Geier-2004" TYPE="STUDY">Geier 2004</LINK>; <LINK REF="STD-Kinzler-1991" TYPE="STUDY">Kinzler 1991</LINK>; <LINK REF="STD-Volz-1997" TYPE="STUDY">Volz 1997</LINK>) who received 200 to 210 mg kavalactones daily (chi square = 7.7; p = 0.02) indicated a non-significant trend (weighted mean difference: 4.5, 95% confidence interval: -0.6 to 9.7; p = 0.08; n = 208). </P>
<P>The results of the five studies that were not submitted to meta-analysis largely support these findings (see characteristics of included studies). <LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK> reported a reduction in favour of kava compared with placebo for the State-Trait Anxiety Inventory. Two studies reported a reduction on the Zung Anxiety Status Inventory (<LINK REF="STD-Gastpar-2003" TYPE="STUDY">Gastpar 2003</LINK>; <LINK REF="STD-Warnecke-1990" TYPE="STUDY">Warnecke 1990</LINK>), whereas <LINK REF="STD-Bhate-1989" TYPE="STUDY">Bhate 1989</LINK> reported a reduction compared with placebo on a 10-Item Anxiety Scale. <LINK REF="STD-Lehmann-1998" TYPE="STUDY">Lehmann 1998</LINK> assessed the responder-non-responder ratio and found a differential effect in favour of kava.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The addition of one new trial (<LINK REF="STD-Connor-2002" TYPE="STUDY">Connor 2002</LINK> ) has reduced the effect by one point on the HAM-A total score, which is of borderline statistical significance. Thus, compared with placebo, kava extract might be an effective symptomatic treatment for anxiety although, at present, the size seems to be small. The effect lacks robustness as indicated by the sensitivity analyses and is based on a relatively small sample. Nonetheless, the reviewed trials which could not be included in the meta-analysis support the findings and suggest that kava is beneficial for patients with anxiety when compared with placebo. This is corroborated by the results of comparative trials (<LINK REF="REF-Boerner-2003" TYPE="REFERENCE">Boerner 2003</LINK>) other systematic reviews (<LINK REF="REF-Jorm-2004" TYPE="REFERENCE">Jorm 2004</LINK>) and previous reviews (<LINK REF="STD-Singh-1998" TYPE="STUDY">Singh 1998</LINK>; <LINK REF="REF-Weber-1994" TYPE="REFERENCE">Weber 1994</LINK>; <LINK REF="REF-Chrubasik-1997" TYPE="REFERENCE">Chrubasik 1997</LINK>; <LINK REF="REF-H_x00e4_nsel-1996" TYPE="REFERENCE">Hänsel 1996</LINK>). However, larger rigorous trials, particularly in long-term studies, are needed. </P>
<P>In our own systematic review assessing the safety of kava (<LINK REF="REF-Stevinson-2002" TYPE="REFERENCE">Stevinson 2002</LINK>), two drug monitoring studies of kava were located. They included a total of 7078 patients taking kava extract equivalent to 105 mg to 240 mg kavalactones per day for 5 to 7 weeks. In these studies no cases of hepatotoxicity emerged, which is supported by a further study (<LINK REF="REF-Connor-2001" TYPE="REFERENCE">Connor 2001</LINK>). Two other postmarketing surveillance studies, including 1673 patients who received kava extract equivalent to 120 mg kavalactones daily for 5 weeks (<LINK REF="REF-Spree-1992" TYPE="REFERENCE">Spree 1992</LINK>) and 2944 other patients who received 400 mg kavain daily for 4 weeks (<LINK REF="REF-Unger-1988" TYPE="REFERENCE">Unger 1988</LINK>) corroborate this and report no hepatotoxic events. Indeed, kava hepatotoxicity seems to be a very rare event (<LINK REF="REF-Teschke-2003" TYPE="REFERENCE">Teschke 2003</LINK>; <LINK REF="REF-Schulze-2003" TYPE="REFERENCE">Schulze 2003</LINK>). No plausible mechanism for the alleged hepatotoxic effects of kava has so far been identified. The question therefore remains whether the frequency of liver damage in kava users differs significantly from that of non-kava users.</P>
<P>Limitations of this meta-analysis pertain to the citation tracking and its potential incompleteness. Although strong efforts were made to locate and retrieve all trials on the subject, it is conceivable that some were not uncovered. The distorting effects on systematic reviews arising from publication bias and location bias are well-documented (<LINK REF="REF-Easterbrook-1991" TYPE="REFERENCE">Easterbrook 1991</LINK>; <LINK REF="REF-Egger-1998" TYPE="REFERENCE">Egger 1998</LINK>). There are also suggestions that positive findings may be overrepresented in complementary medicine journals (<LINK REF="REF-Ernst-1997" TYPE="REFERENCE">Ernst 1997</LINK>; <LINK REF="REF-Schmidt-2001" TYPE="REFERENCE">Schmidt 2001</LINK>, <LINK REF="REF-Pittler-2000b" TYPE="REFERENCE">Pittler 2000b</LINK>). In addition, there is evidence for the tendency of positive findings to be published in English language journals (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) and for some European journals to not be indexed in major medical databases (<LINK REF="REF-Nieminen-1999" TYPE="REFERENCE">Nieminen 1999</LINK>). Therefore the possibility of treatment effects to be exaggerated exists, which may be particularly relevant to herbal medicinal products where much of the evidence originates from European countries. Databases searched for the purposes of this study included those with a focus on the American and European literature and those that specialize in complementary medicine. There were no restrictions in terms of publication language. We are therefore confident that this strategy has minimized bias in the present study. </P>
<P>Other pharmacological options include antidepressants and benzodiazepines. The latter, however, may cause adverse events such as sedation, amnesia, developement of tolerance and carry an increased risk of road-traffic accidents (<LINK REF="REF-Barbone-1998" TYPE="REFERENCE">Barbone 1998</LINK>; <LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>; <LINK REF="REF-O_x0027_Neill-1998" TYPE="REFERENCE">O'Neill 1998</LINK>). Comparative studies that were identified during the searches suggest the absence of significant differences between benzodiazepines and kavain or kava extract (<LINK REF="STD-Lindenberg-1990" TYPE="STUDY">Lindenberg 1990</LINK>; <LINK REF="REF-Woelk-1993" TYPE="REFERENCE">Woelk 1993</LINK>) in terms of effectiveness. However, a systematic assessment is required for firm statements. Also, more equivalence studies are needed, not least to define the relative risks of both approaches.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Compared with placebo, kava extract is an effective symptomatic treatment for anxiety although, at present, the size of the effect seems to be small. The effect lacks robustness and is based on a relatively small sample. The data available from the reviewed studies suggest that kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Rigorous trials with large sample sizes are needed to clarify the existing uncertainties. Also, long-term safety studies of kava are required.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Conception and design: MH Pittler, E Ernst<BR/>Literature searches: MH Pittler<BR/>Analysis and interpretation of the data: MH Pittler, E Ernst<BR/>Drafting of the article: MH Pittler, E Ernst<BR/>Critical revision of the article for important intellectual content: MH Pittler, E Ernst<BR/>Final approval of the article: MH Pittler, E Ernst</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-03-12 09:33:26 +0000" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhate-1989" NAME="Bhate 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhate H, Gerster G, Gracza E</AU>
<TI>Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie</TI>
<SO>Erfahrungsheilkunde</SO>
<YR>1989</YR>
<VL>38</VL>
<NO>6</NO>
<PG>339-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connor-2002" NAME="Connor 2002" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Davidson JR</AU>
<TI>A placebo-controlled study of kava kava in generalized anxiety disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>4</NO>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gastpar-2003" NAME="Gastpar 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gastpar M, Klimm HD</AU>
<TI>Treatment of anxiety, tension and restlessness states with kava special extract WS1490 in general practice: A randomized placebo-controlled double-blind multicenter trial</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>10</NO>
<PG>631-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geier-2004" NAME="Geier 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geier FP, Konstantinowicz T</AU>
<TI>Kava treatment in patients with anxiety</TI>
<SO>Phytotherapy Research</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>4</NO>
<PG>297-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinzler-1991" NAME="Kinzler 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinzler E, Krömer J, Lehmann E</AU>
<TI>Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis Double blind study with placebos over 4 weeks</TI>
<TO>Wirksamkeit eines Kava-Spezial-Extraktes bei Patieinten mit Angst-, Spannungs- und Erregungszuständen nicht-psychotischer Genese</TO>
<SO>Arzneimittelforschung</SO>
<YR>1991</YR>
<VL>41</VL>
<NO>6</NO>
<PG>584-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1998" NAME="Lehmann 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann E</AU>
<TI>Wirkung bei Kava - Kava bei akuter Angst</TI>
<SO>Synopsis</SO>
<YR>1998</YR>
<VL>2</VL>
<PG>57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehrl-2004" NAME="Lehrl 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehrl S</AU>
<TI>Clinical efficacy of kava extract WS1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter randomized placebo-controlled double-blind clinical trial</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2004</YR>
<VL>78</VL>
<NO>2</NO>
<PG>101-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malsch-2001" NAME="Malsch 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malsch U, Kieser M</AU>
<TI>Efficacy of kava-kava in the treamtent of non-psychotic anxiety, following pretreatment with benzodiazepines</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>157</VL>
<NO>3</NO>
<PG>277-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1998" NAME="Singh 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh NN, Ellis CR, Sharp I, Eakin K, Best AM, Singh YN</AU>
<TI>A double-blind, placebo-controlled study of the effects of kava (Kavatrol) on daily stress and anxiety in adults</TI>
<SO>Alternative Therapies (Natrol in-house publication 1997)</SO>
<YR>1998</YR>
<VL>4</VL>
<PG>97-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volz-1997" NAME="Volz 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volz HP, Kieser M</AU>
<TI>Kava-kava extract WS1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial</TI>
<SO>PharmacopsychiatRY</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warnecke-1990" NAME="Warnecke 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warnecke G, Pfaender H, Gerster G, Gracza E</AU>
<TI>Efficacy of an extract of Kavaroot in patients with climacteric syndrome</TI>
<TO>Wirksamkeit von Kawa-Kawa-Extrakt beim klimakterischen Syndrom</TO>
<SO>Zeitschrift fur Phytotherapie</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>3</NO>
<PG>81-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warnecke-1991" NAME="Warnecke 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warnecke G</AU>
<TI>Psychosomatic dysfunctions in the female climacteric Clinical effectiveness and tolerance of Kava Extract WS-1490</TI>
<TO>Psychosomatische Dysfunktionen im weiblichen Klimakterium Klinische Wirksamkeit und Vertraglichkeit von KavaExtrakt WS 1490</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1991</YR>
<VL>109</VL>
<NO>4</NO>
<PG>119-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhate-1992" NAME="Bhate 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhate H, Gerster G</AU>
<TI>Behandlung mit Phytotranquilizern vor der Narkose</TI>
<SO>Therapeutikon</SO>
<YR>1992</YR>
<VL>6</VL>
<PG>214-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Leo-2001" NAME="De Leo 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Leo V, La Marca A, Morgante G, Lanzetta D, Floria P, Petraglia F</AU>
<TI>Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety</TI>
<SO>Maturitas</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>2</NO>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1989" NAME="Lehmann 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann E, Klieser E, Klimke A, Krach H, Spatz R</AU>
<TI>The efficacy of cavain in patients suffering from anxiety</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1989</YR>
<VL>22.</VL>
<NO>6</NO>
<PG>258-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1996" NAME="Lehmann 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann E, Kinzler E, Friedmann J</AU>
<TI>Efficacy of a special kava extract (Piper methysticum) in patients with states of anxiety, tension and exitedness of non-mental origin - a double-blind placebo-controlled study of four weeks treatment</TI>
<SO>Phytomedicine</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>2</NO>
<PG>113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindenberg-1990" NAME="Lindenberg 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenberg D, Pitule-Schödel H</AU>
<TI>D,L-kavain in comparison with oxazepam in anxiety disorders A double-blind study of clinical effectiveness</TI>
<TO>D,L-Kavain im Vergleich zu Oxazepam bei Angstzuständen. Doppelblindstudie aur Wirksamkeit</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1990</YR>
<VL>108</VL>
<NO>2</NO>
<PG>49-50, 53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1989" NAME="Möller 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Heuberger L</AU>
<TI>Anxiolytic potency of D,L-kavain. Results of a placebo-controlled, double-blind study</TI>
<TO>Anxiolytische Potenz von D,L-Kavain</TO>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1989</YR>
<VL>131</VL>
<NO>37</NO>
<PG>656-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1992" NAME="Möller 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Ulm K, Glöggler A</AU>
<TI>Kavain as an aid in the withdrawal of benzodiazepines (Therapy study)</TI>
<TO>Kavain als Hilfe beim Benzodiazepin-Entzug</TO>
<SO>Munchener Medizinische Wochenschrift</SO>
<YR>1992</YR>
<VL>134</VL>
<NO>37</NO>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staedt-1991" NAME="Staedt 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staedt U, Holm E, Heep J, Riesmüller S, Kortsik C, Steiner G</AU>
<TI>Studies on effects of D,L-Kawain-psychometry, EEG and Hamilton scale</TI>
<TO>Zum Wirkungsprofil von D,L-Kavain</TO>
<SO>Medizinische Welt</SO>
<YR>1991</YR>
<VL>42</VL>
<NO>10</NO>
<PG>881-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warnecke-1986" NAME="Warnecke 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warnecke G, Gerster G, Jäger H</AU>
<TI>Anxiolytic effect with a phytotranquilizer in gynecology</TI>
<TO>Anxiolyse mit einem Phyto-Tranquilizer in der Frauenheilkunde</TO>
<SO>Medizinische Welt</SO>
<YR>1986</YR>
<VL>37</VL>
<NO>44</NO>
<PG>1379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warnecke-1989" NAME="Warnecke 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warnecke G</AU>
<TI>Langzeittherapie psychischer und vegetativer Dysrepulationen mit Zubereitungen aus Piper methysticum</TI>
<SO>Erfahrungsheilkunde</SO>
<YR>1989</YR>
<VL>38</VL>
<NO>6</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-03-12 09:33:26 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-03-12 09:33:26 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Astin-1998" MODIFIED="2010-03-12 09:25:26 +0000" MODIFIED_BY="[Empty name]" NAME="Astin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Astin JA</AU>
<TI>Why patients use alternative medicine. Results of a national study</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<PG>1548-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbone-1998" NAME="Barbone 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG et al</AU>
<TI>Association of road-traffic accidents with benzodiazepine use</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumenthal-2001" NAME="Blumenthal 2001" TYPE="JOURNAL_ARTICLE">
<AU>Blumenthal M</AU>
<TI>Herb sales down 15 percent in mainstream market</TI>
<SO>Herbalgram</SO>
<YR>2001</YR>
<VL>51</VL>
<PG>69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boerner-2003" NAME="Boerner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M</AU>
<TI>Kava kava extract LI150 is as effective as opipramol and buspirone in generalized anxiety disorder - An 8-week randomized double-blind multi-centre clinical trial in 129 out-patients</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>38-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brevoort-1998" NAME="Brevoort 1998" TYPE="JOURNAL_ARTICLE">
<AU>Brevoort P</AU>
<TI>The booming US botanical market - a new overview</TI>
<SO>Herbalgram</SO>
<YR>1998</YR>
<VL>44</VL>
<PG>33-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cawte-1985" NAME="Cawte 1985" TYPE="JOURNAL_ARTICLE">
<AU>Cawte J</AU>
<TI>Psychoactive substances of the south seas: betel, kava and pituri</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>19</VL>
<PG>83-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chrubasik-1997" NAME="Chrubasik 1997" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S</AU>
<TI>Klinisch geprüfte Wirksamkeit bei nervösen Angst-, Spannungs- und Unruhezuständen</TI>
<SO>Der Allgemeinarzt</SO>
<YR>1997</YR>
<VL>18</VL>
<PG>1683-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connor-2001" NAME="Connor 2001" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Davidson JR, Churchill LE</AU>
<TI>Adverse-effect profile of kava</TI>
<SO>CNS Spectrum</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>848-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deans-1992" NAME="Deans 1992" TYPE="JOURNAL_ARTICLE">
<AU>Deans HG, Skinner P</AU>
<TI>Doctors' views on anxiety management in general practice</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1992</YR>
<VL>85</VL>
<PG>83-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Easterbrook-1991" NAME="Easterbrook 1991" TYPE="JOURNAL_ARTICLE">
<AU>Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR</AU>
<TI>Publication bias in clinical research</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1998" NAME="Egger 1998" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD</AU>
<TI>Bias in location and selection of studies</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ernst-1997" NAME="Ernst 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ernst E, Pittler MH</AU>
<TI>Alternative therapy bias</TI>
<SO>Nature</SO>
<YR>1997</YR>
<VL>385</VL>
<PG>480</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gorman-1990" MODIFIED="2010-03-12 09:33:26 +0000" MODIFIED_BY="[Empty name]" NAME="Gorman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gorman JM, Papp LA</AU>
<TI>Chronic anxiety: deciding the length of treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51 Suppl 1</VL>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-1999" NAME="Greenberg 1999" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR et al</AU>
<TI>The economic burden of anxiety disorders in the 1990s</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<PG>427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Habs-1994" NAME="Habs 1994" TYPE="JOURNAL_ARTICLE">
<AU>Habs M, Honold E</AU>
<TI>Der psychoaktive Spezialextrakt WS 1490 aus dem Wurzelstock von Piper methysticum (Kava-Kava) - ein Report</TI>
<SO>Forschende Komplementarmedizin</SO>
<YR>1994</YR>
<VL>1</VL>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmann-1996" NAME="Hofmann 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hofmann R, Winter U</AU>
<TI>Therapeutische Möglichkeiten mit Kava-Kava bei Angsterkrankungen</TI>
<SO>Psycho</SO>
<YR>1996</YR>
<VL>22 Suppl</VL>
<PG>51-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunt-1991" NAME="Hunt 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hunt C, Singh M</AU>
<TI>Generalized anxiety disorder</TI>
<SO>International Review of Psychiatry</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>215-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00e4_nsel-1996" MODIFIED="2010-03-12 09:25:52 +0000" MODIFIED_BY="[Empty name]" NAME="Hänsel 1996" TYPE="BOOK">
<AU>Hänsel R, Kammerer S</AU>
<SO>Kava-Kava</SO>
<YR>1996</YR>
<PB>Aesopus</PB>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore A, Carroll D Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomised clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorm-2004" NAME="Jorm 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jorm AF, Christensen H, Griffiths KM, Parslow RA, RodgersRA, Blewitt KA</AU>
<TI>Effectiveness of complementary and self-help treatments for anxiety disorders</TI>
<SO>MJA</SO>
<YR>2004</YR>
<VL>181</VL>
<PG>S29-S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1994" NAME="Kessler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al</AU>
<TI>Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-2001" NAME="Kessler 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, Soukup J, Davis RB, Foster DF, Wilkey SA, Van Rompay MI et al</AU>
<TI>The use of complementary and alternative therapies to treat anxiety and depression in the United States</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<PG>289-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lebot-1992" NAME="Lebot 1992" TYPE="BOOK">
<AU>Lebot V, Merlin M, Lindstrom L</AU>
<SO>Kava, the pacific drug</SO>
<YR>1992</YR>
<PB>Yale University Press</PB>
<CY>New Haven, CT</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lemert-1967" NAME="Lemert 1967" TYPE="JOURNAL_ARTICLE">
<AU>Lemert EM</AU>
<TI>Secular use of kava in Tonga</TI>
<SO>Journal of Ethnopharmacology</SO>
<YR>1967</YR>
<VL>28</VL>
<PG>328-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melville-1964" NAME="Melville 1964" TYPE="BOOK">
<AU>Melville H.</AU>
<SO>Typee: a peep at Polynesian life during a four months' residence in a valley of the Marquesas</SO>
<YR>1964</YR>
<PB>Signet</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1998" NAME="Moore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Muir Gray JA</AU>
<TI>Benzodiazepines and car crashes</TI>
<SO>Bandolier</SO>
<YR>1998</YR>
<VL>57</VL>
<PG>6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myers-1984" NAME="Myers 1984" TYPE="JOURNAL_ARTICLE">
<AU>Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel H et al</AU>
<TI>Six-month prevalence of psychiatric disorders in three communities 1980 to 1982</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<PG>959-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nieminen-1999" NAME="Nieminen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nieminen P, Isohanni M</AU>
<TI>Bias against European journals in medical publication databases</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>1592</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Neill-1998" NAME="O'Neill 1998" TYPE="JOURNAL_ARTICLE">
<AU>O'Neill D</AU>
<TI>Benzodiazepines and driver safety</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1324-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2000a" NAME="Pittler 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Pittler MH, Ernst E</AU>
<TI>Efficacy of kava extract for treating anxiety: systematic review and meta-analysis</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>84-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2000b" NAME="Pittler 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Pittler MH, Abbot NC, Harkness EF, Ernst E</AU>
<TI>Location bias in controlled clinical trials of complementary/alternative therapies</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<PG>485-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priest-1988" NAME="Priest 1988" TYPE="JOURNAL_ARTICLE">
<AU>Priest RG, Montgomery SA</AU>
<TI>Benodiazepines and dependence: a college statement</TI>
<SO>Bulletin of the Royal College of Psychiatrists</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>107-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1993" NAME="Robinson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Robinson MD</AU>
<TI>Anxiety disorders in the general practice</TI>
<SO>New Jersey medicine : the journal of the Medical Society of New Jersey</SO>
<YR>1993</YR>
<VL>90</VL>
<PG>129-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-2001" NAME="Schmidt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt K, Pittler MH, Ernst E</AU>
<TI>Bias in alternative medicine is still rife but is diminishing</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1071</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulze-2003" NAME="Schulze 2003" TYPE="JOURNAL_ARTICLE">
<AU>Schulze J, Raasch W, Siegers CP</AU>
<TI>Toxicity of kava pyrones, drug safety and precautions - a case study</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>68-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siegers-1990" NAME="Siegers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Siegers CP, Honold E, Krall B, Meng G, Habs M</AU>
<TI>Ergebnisse einer Anwendungsbeobachtung L1090 mit Laitan® Kapseln</TI>
<SO>Ärztliche Forschung</SO>
<YR>1992</YR>
<VL>39</VL>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-1998" NAME="Singh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Singh YN, Blumenthal M</AU>
<TI>Kava, an overview</TI>
<SO>Herbalgram</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>33-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spree-1992" NAME="Spree 1992" TYPE="JOURNAL_ARTICLE">
<AU>Spree MH, Croy HH</AU>
<TI>Antares - ein standardisiertes Kava-Kava Präparat mit dem Spezialextrakt KW 1491</TI>
<SO>Der Kassenarzt</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>44-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevinson-2002" NAME="Stevinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stevinson C, Huntley A, Ernst</AU>
<TI>A systematic review of the safety of kava extract in the treatment of anxiety</TI>
<SO>Drug Safety</SO>
<YR>2002</YR>
<VL>25</VL>
<PG>251-61.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teschke-2003" NAME="Teschke 2003" TYPE="JOURNAL_ARTICLE">
<AU>Teschke R, Gaus W, Loew D</AU>
<TI>Kava extracts: Safety and risks including rare hepatoxicity</TI>
<SO>Phytomedicine</SO>
<YR>2003</YR>
<VL>10</VL>
<PG>440-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Unger-1988" NAME="Unger 1988" TYPE="JOURNAL_ARTICLE">
<AU>Unger L</AU>
<TI>Veränderung psychovegetativer Beschwerden unter Therapie mit Kavain</TI>
<SO>Therapiewoche</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>3171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walley-1994" NAME="Walley 1994" TYPE="JOURNAL_ARTICLE">
<AU>Walley EJ, Beebe DK, Clark JL</AU>
<TI>Management of common anxiety disorders</TI>
<SO>American Family Physician</SO>
<YR>1994</YR>
<VL>50</VL>
<PG>1745-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weber-1994" NAME="Weber 1994" TYPE="JOURNAL_ARTICLE">
<AU>Weber U, Winter U</AU>
<TI>Kava-Kava - ein pflanzliches Anxiolytikum</TI>
<SO>Fundamenta Psychiatrica</SO>
<YR>1994</YR>
<VL>8</VL>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woelk-1993" NAME="Woelk 1993" TYPE="JOURNAL_ARTICLE">
<AU>Woelk H, Kapoula O, Lehrl S, Schröter K, Weinholz P</AU>
<TI>Behandlung von Angst-Patienten</TI>
<SO>Zeitschrift fuer Allgemeinmedizin</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bhate-1989">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pre-operative patients (n=59); General hospital, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>300 mg (60 mg kavalactones) night before operation and 300 mg (60 mg) 1 hour before operation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>10-Item Anxiety Scale. Differential reduction of anxiety in favour of kava (p&lt;0.05)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): postoperative hangover<BR/>Jadad score: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Connor-2002">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Outpatients with generalized anxiety disorder (DSM-IV) ; HAMA total score 16 or above (per-protocol; n=35); University outpatient setting, US</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>140 mg kavalactones daily for 1 week, then 280 mg kavalactones daily for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval -2.8; -5.4 to -0.2<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>'No evidence of withdrawal or sexual side effects'<BR/>Jadad score: 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gastpar-2003">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind, multicenter; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Outpatients with neurotic anxiety (DSM-III-R) ; HAMA total score 19 or above (intention-to-treat; n=141); 17 general practices in Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>50 mg 3 times (105 mg kavalactones) daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Zung Anxiety Status Inventory. Reduction compared with baseline in kava group (p&lt;0.001)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): tiredness, symptom aggravation, unrelated to the investigational treatment (not detailed), <BR/>Jadad score: 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Geier-2004">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with nonpsychotic anxiety (DSM-III-R) ; HAMA total score 19 or above (intention-to-treat; n=50); Hospital setting, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>50 mg 3 times (105 mg kavalactones) daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval 0.4; -3.5 to 4.3<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): Pleuro pneumonia; deterioration of pre-existing pulmonary fibrosis<BR/>Jadad score: 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kinzler-1991">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Outpatients with nonpsychotic anxiety syndrome (ICD 9); HAMA 19 or above (intention-to-treat; n=58); University outpatient setting, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>100 mg 3 times (210 mg kavalactones) daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval 8.7; 4.3 to 13.1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): none<BR/>Jadad score: 5<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lehmann-1998">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind;2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pre-operative women (n=20); University hospital, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>150 mg 3 times (150 mg kavalactones) daily for 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Responder - non-responder ratio. Differential reduction of anxiety in favour of kava (p&lt;0.05)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): not detailed <BR/>Jadad score: 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lehrl-2004">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind, multicenter; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with sleep disturbances associated with nonpsychotic anxiety (DSM-III-R) ; HAMA total score 16 or above (intention-to-treat; n=57); 3 centers in Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>200 mg once (140 mg kavalactones) daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval 1.4; -3.4 to 6.2</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): none<BR/>Jadad score: 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Malsch-2001">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Outpatients with nonpsychotic anxiety and pretreatment with benzodiazepines (DSM-III-R); HAMA total score of 14 or below (median at baseline: 13 kava / 13 placebo; intention-to-treat; n=40); General Hospital, Hamburg, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tapering off benzodiazepines and increase from 50 to 300 mg (210 mg kavalactones) daily for 1 week. Then 100 mg 3 times daily for 3 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval 2.4; -1.5 to 6.3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): not detailed <BR/>Jadad score: 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Singh-1998">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with anxiety diagnosed using the State Trait Anxiety Inventory (n=60); University setting, US</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>400 mg 2 times (240 mg kavalactones) daily for 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>State-trait Anxiety Inventory. Differential reduction in favour of kava (p&lt;0.0001); no differential effect for trait anxiety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): none<BR/>Jadad score: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Volz-1997">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind, multicenter; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Outpatients with nonpsychotic anxiety (DSM-III-R); HAMA total score 19 or above (intention-to-treat; n=100); General practice, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>100 mg 3 times (210 mg kavalactones) daily for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval 4.8; -0.6 to 10.2</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): not detailed; stomach upset were rated by the investigators as possibly related to the intake of kava<BR/>Jadad score: 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Warnecke-1990">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Female outpatients with anxiety due to climacteric syndrome (n=40); Gynaecology practice, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>150 mg 2 times (60 mg kavalactones) daily for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Zung Anxiety Status Inventory. Reduction compared with baseline in kava group (p&lt;0.001); no effect in placebo group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): headache, tiredness and lack of energy; stomach complaints, heartburn and diarrhoea<BR/>Jadad score: 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Warnecke-1991">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double-blind; 2 parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Female outpatients with anxiety due to climacteric syndrome; HAMA total score 19 or above (intention-to-treat; n=40); Gynaecology practice, Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>100 mg 3 times (210 mg kavalactones) daily for 8 weeks <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A total score. Mean difference, 95% confidence interval 17.9; 9.0 to 26.9</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Adverse events (kava group): restlessness, stomach complaints, drowsiness, tremor<BR/>Jadad score: 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bhate-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Leo-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>conducted in combination with hormone replacement therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lehmann-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a single constituent of kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lehmann-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>duplicate publication (translated from Kienzler E et al . 1991)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindenberg-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a single constituent of kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-M_x00f6_ller-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a single constituent of kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-M_x00f6_ller-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a single constituent of kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Staedt-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a single constituent of kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Warnecke-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a combination preparation containing kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Warnecke-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>assessed a combination preparation containing kava extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bhate-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Connor-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gastpar-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geier-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kinzler-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lehmann-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lehrl-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Malsch-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Volz-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Warnecke-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Warnecke-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-03-12 09:26:22 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-03-12 09:26:22 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Kava versus placebo for anxiety</NAME>
<CONT_OUTCOME CHI2="27.466800281556456" CI_END="7.659100768624768" CI_START="0.04717617727572465" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="3.8531384729502465" ESTIMABLE="YES" I2="78.15544607127424" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.1836763330097533E-4" P_Q="1.0" P_Z="0.04722704176194142" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="19.889596071772118" TOTALS="YES" TOTAL_1="197" TOTAL_2="183" UNITS="" WEIGHT="99.99999999999999" Z="1.9842583945224606">
<NAME>Improvement (HAMA-score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3007988134024986" CI_START="-6.900798813402498" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="8.5" ORDER="28" SD_1="7.6" SD_2="4.2" SE="2.0922827387386076" STUDY_ID="STD-Connor-2002" TOTAL_1="17" TOTAL_2="18" WEIGHT="15.538616198018282"/>
<CONT_DATA CI_END="4.284092825954339" CI_START="-3.4840928259543413" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="12.3" ORDER="29" SD_1="6.7" SD_2="7.3" SE="1.9817164277464119" STUDY_ID="STD-Geier-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="15.832498042725371"/>
<CONT_DATA CI_END="13.101462736983272" CI_START="4.29853726301673" EFFECT_SIZE="8.700000000000001" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="3.6" ORDER="30" SD_1="8.7" SD_2="8.4" SE="2.2456855185612836" STUDY_ID="STD-Kinzler-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="15.123888886845885"/>
<CONT_DATA CI_END="6.166856055473712" CI_START="-3.3668560554737113" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="9.2" ORDER="31" SD_1="7.3" SD_2="10.0" SE="2.432114106725462" STUDY_ID="STD-Lehrl-2004" TOTAL_1="34" TOTAL_2="23" WEIGHT="14.612775183291868"/>
<CONT_DATA CI_END="6.255952069916924" CI_START="-1.4559520699169246" EFFECT_SIZE="2.4" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="0.6" ORDER="32" SD_1="7.5" SD_2="4.6" SE="1.9673586353280887" STUDY_ID="STD-Malsch-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="15.870279987558876"/>
<CONT_DATA CI_END="10.171234127026477" CI_START="-0.5712341270264751" EFFECT_SIZE="4.800000000000001" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="16.2" ORDER="33" SD_1="13.0" SD_2="14.3" SE="2.740475931901854" STUDY_ID="STD-Volz-1997" TOTAL_1="52" TOTAL_2="48" WEIGHT="13.762119306226124"/>
<CONT_DATA CI_END="26.905791797382186" CI_START="9.014208202617816" EFFECT_SIZE="17.96" ESTIMABLE="YES" MEAN_1="25.61" MEAN_2="7.65" ORDER="34" SD_1="12.8" SD_2="15.9" SE="4.564263357870578" STUDY_ID="STD-Warnecke-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.259822395333586"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Comment Safety warns about kava</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>We've been alerted to safety concerns about kava products, noting that Swiss and German authorities have withdrawn these from the market after concerns about liver toxicity. The US FDA is also investigating the status of kava. We have added a notice to the Cochrane Consumer Network website, but would like to see this information included in the review as a matter of urgency. We believe that consumers would like to know that some countries believe these products may not be safe.</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Please see response to Comment Number 02.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment Safety warns about kava<BR/>Sender Hilda Bastian<BR/>Sender Email hilda.bastian@cochraneconsumer.com<BR/>Date Received 19/03/02 04:27:00</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" NO="2">
<TITLE>Comment Update on safety warnings for kava</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>New information has surfaced since the message posted on 19/3/02. In addition, one correction is in order for this earlier message.</P>
<P>The US Food and Drug Administration issued a Consumer Advisory on 25/03/2002 (http://www.cfsan.fda.gov/%7Edms/addskava.html) in which it "advises consumers of the potential risk of severe liver injury associated with the use of kava-containing dietary supplements." The agency recommends that "persons who have liver disease or liver problems, or persons who are taking drug products that can affect the liver, should consult a physician before using kava-containing supplements." The agency also urges both consumers and physicians to report cases of liver or other injuries that may be associated with kava.</P>
<P>The American Herbal Products Association adopted the following labeling recommendation for kava products on 26/03/02: "Caution: Ask a healthcare professional before use if you have or have had liver problems, frequently use alcoholic beverages, or are taking any medication. Stop use and see a doctor if you develop symptoms that may signal liver problems (e.g., unexplained fatigue, abdominal pain, fever, vomiting, dark urine, yellow eyes or skin). Not for use by persons under 18 years of age, or by pregnant or breastfeeding women. Not for use with alcoholic beverages. Excessive use, or use with products that cause drowsiness, may impair your ability to operate a vehicle or heavy equipment."</P>
<P>Hilda Bastien's 19/03/02 message should be corrected to note that German health authorities have not, in fact, withdrawn kava products. Rather, they proposed withdrawal in November, 2001 and requested information to evaluate their proposal. It is my understanding that no final decision has yet been made. Similarly, while some kava products have been removed from the Swiss market, others continue to be sold there.</P>
<P>US FDA was cautious in its communication to refer to any association between kava and the liver as "potential." Nevertheless, the recommendation made by Bastien that consumers be informed of the current concerns that have been expressed by health authorities is sound and is supported by the U.S. herbal trade.</P>
<P>As the President of a trade association that represents manufacturers and marketers of herbal products, including kava products, I have a periferal affiliation with companies that do have a financial interst in this matter. I certify that I have no commercial affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>At the time of writing (August 2002) 68 documented cases of suspected kava hepatotoxicity were on record worldwide. In many of these instances, the exact nature of the extract was not specified. It is clear, however, that all types of extract and synthetic kavain are implicated. In the vast majority of these cases other drugs - some with known hepatotoxicity - were taken concomitantly, a fact, which considerably complicates causal attribution. Similarly, in many of these case reports no data for alcohol consumption or viral infection are provided. The problems typically occurred 2 to 3 months after kava intake; in some cases the length of kava use was not known. The adverse events ranged from mere transient elevations of liver enzymes to severe (often cholestatic) hepatitis and fulminant liver failure. In most instances the patients seemed to have recovered fully after discontinuation of kava. However, 6 patients required liver transplants and 3 patients died. Reliable incidence or prevalence figures are not currently available.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment Update on safety warnings for kava<BR/>Sender Michael McGuffin<BR/>Sender Description President, American Herbal Products Association<BR/>Sender Email mmcguffin@ahpa.org<BR/>Sender Address 8484 Georgia Ave., #370 Silver Spring, MD 20910 USA<BR/>Date Received 14/06/02 16:33:23</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>